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Abstract
Unlike tuberculous peritonitis, peritonitis due to non-tuberculous mycobacteria (NTM) has unclear clinical manifestations. This study
aimed to clarify the clinical manifestations and laboratory results of NTM peritonitis and compare it to tuberculous peritonitis. This ret-
rospective study was conducted from 2000 to 2008 in a medical centre in Taiwan. Patients with mycobacteria isolated from ascites
were identiﬁed and compared according to causative pathogens (Mycobacterium tuberculosis or NTM). Those with NTM peritonitis were
further classiﬁed into the ‘probable’ and ‘possible’ groups based on diagnostic evidence. Twenty-ﬁve patients with NTM peritonitis and
65 with tuberculous peritonitis were reviewed. Mycobacterium avium complex was the most common NTM pathogen (52%). There was
no obvious difference between the ‘probable’ and ‘possible’ NTM peritonitis groups regarding age and laboratory data. Patients with
NTM peritonitis and those with tuberculous peritonitis had no differences in age or gender but varied in symptoms and serum labora-
tory data. NTM peritonitis was 100% associated with underlying co-morbidities and had lower proportions of lymphocytes and albumin
level in ascites. Twelve (48%) NTM peritonitis and 21 (32%) tuberculous peritonitis patients died during the 6-month follow-up. Anti-
mycobacterial treatment, but not mycobacterial species, was correlated with better 6-month survival. In Taiwan, NTM is responsible
for 28% of mycobacterial peritonitis cases, which have a poor prognosis if untreated. There are some differences in clinical manifesta-
tions between NTM and tuberculous peritonitis. NTM peritonitis should be considered in patients with peritonitis but without causative
microorganisms identiﬁed other than NTM.
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Introduction
Diagnosis of extrapulmonary mycobacterial infections is com-
plicated due to variable manifestations and difﬁculty in col-
lecting clinical samples [1]. One such infection is
mycobacterial peritonitis. Though uncommon, mycobacterial
peritonitis has a high mortality rate, especially in immuno-
compromised hosts [1]. Most reported cases are caused by
Mycobacterium tuberculosis. However, due to ageing, increas-
ing numbers of immunocompromised individuals, and
advances in non-tuberculous mycobacteria (NTM) isolation
[2–5], the overall incidence of NTM disease has increased in
recent years [5–8]. From a clinical standpoint, it is important
to know the relative proportions of tuberculosis (TB) and
NTM disease in patients with mycobacterial peritonitis.
The clinical characteristics of NTM peritonitis remain
unclear. Ding et al. reported 11 cases of abdominal NTM
infection with a mortality rate of 73% [9]. In their series,
55% had liver cirrhosis and only 18% received anti-NTM
treatment. Liver cirrhosis further increases the difﬁculty of
early diagnosis of mycobacterial peritonitis because the
transudative ascites may mask the peritoneal inﬂammation
while the bleeding tendency prevents invasive diagnostic pro-
cedures such as peritoneal biopsy.
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Because anti-NTM treatment can improve survival in
NTM lung disease [10], familiarity with the presentations of
NTM peritonitis is of practical importance for early diagnosis
and prompt treatment. This retrospective study aimed to
clarify the clinical manifestations and laboratory results of
NTM peritonitis and compare them with TB peritonitis.
Materials and Methods
This study was conducted in a tertiary referral centre in
northern Taiwan and the Institutional Review Board of the
Research Ethics Committee approved the study design (No.
201002023R). Medical records and the mycobacterial labora-
tory registry database were reviewed. In our hospital, myco-
bacteriological study is routinely performed for the ﬁrst
ascites sample of every patient and for multiple ascites sam-
ples of those whose ascites has no deﬁnite aetiology, is exu-
dative, or responds poorly to treatment [11]. Mycobacterial
culture and identiﬁcation were performed as previously
described [12,13] and quality control assessment of the
mycobacterial laboratory was periodically performed by the
National Reference Laboratory of the Centres for Disease
Control of Taiwan.
All of the patients with ascites samples sent for mycobac-
terial culture from January 2000 to December 2008 were eli-
gible. In order to know the whole picture of culture-
conﬁrmed mycobacterial peritonitis, all of the patients whose
samples yielded mycobacteria were recruited and those with
concomitant bacterial or cancerous peritonitis were not
excluded. The ﬁrst positive ascites sample was deﬁned as the
index sample. The recruited patients were classiﬁed into TB
and NTM peritonitis groups. Because NTM was ubiquitous in
the environment and laboratory contamination was possible,
NTM patients were further classiﬁed into two groups. Those
with additional diagnostic evidences of NTM, including (i)
more than one specimen of ascites yielding the same NTM,
(ii) having the same NTM species growing in specimens
other than ascites or (iii) presence of tissue pathology com-
parable for mycobacterial infection, were deﬁned as the
‘probable group’. Those with single ascites culture positive
for NTM were deﬁned as the ‘possible group’.
A specially designed reporting form was used to collect
data on the clinical characteristics, laboratory ﬁndings, treat-
ment course and outcomes. Patients were followed-up for at
least 6 months after the index sample or until death or lost
to follow-up. The end of follow-up date was deﬁned as the
last-visit date for the last group. Mycobacteria-related mor-
tality was considered sepsis complicated by multi-organ fail-
ure with no evidence of pathogens other than mycobacteria.
Proper anti-tuberculous and anti-NTM regimens were
deﬁned according to the TB treatment guidelines established
by the American Thoracic Society [14,15]. Gastrointestinal
symptoms included vomiting, haematemesis, tarry stool and
haematochezia. The disease was considered disseminated if
samples other than ascites yielded the same mycobacteria
[15]. The duration from presentation to diagnosis of myco-
bacterial peritonitis was considered prolonged if it was
>6 weeks [16]. Alcoholism was diagnosed when a patient
had alcohol abuse or dependence (with history of alcohol
withdrawal or tolerance) [17].
Three histological ﬁndings from peritoneal tissues were
considered typical for mycobacterial infection: (i) granuloma-
tous inﬂammation, (ii) caseous necrosis or (iii) the presence
of acid-fast bacilli [18]. Child–Pugh classiﬁcation for liver cir-
rhosis was scored according to a previous report [19]. The
estimated glomerular ﬁltration rate was obtained using the
Modiﬁcation of Diet in Renal Disease Study equation [20].
Severe chronic renal disease was deﬁned as an estimated glo-
merular ﬁltration rate of £30 mL/min/1.73 m2.
Statistical analysis
Inter-group differences were compared using the Student
t-test or one-way ANOVA for numerical variables, where
appropriate, while the chi-square test was used for categori-
cal variables. Six-month survival curves for each variable
were generated using the Kaplan–Meier method and com-
pared using the log-rank test. Variables with a signiﬁcant dif-
ference in univariate analysis were entered into the Cox
proportional hazard regression analysis. A two-sided p <0.05
was considered statistically signiﬁcant. All analyses were
performed with the SPSS software (version 13.0; SPSS Inc.,
Chicago, IL, USA).
Results
During the study period, 10 781 ascites samples from 5298
patients were sent for mycobacterial study, and 65 patients
with TB peritonitis and 25 with NTM peritonitis were
identiﬁed. MAC was the most common NTM species
(n = 13), followed by rapidly growing mycobacteria (n = 7).
Of the NTM group, 8 (32%) and 17 (68%) patients were
classiﬁed into the ‘probable’ and ‘possible’ groups, respec-
tively (Tables 1 and 2). In the ‘probable group’, eight had
additional culture evidence and three had comparable pathol-
ogy of mycobacterial infection. Co-bacterial peritonitis with
Salmonella sp. was noted in one patient with MAC peritonitis
and of three patients with TB peritonitis, two patients had
Escherichia coli and one had Candida albicans. Cytology-proven
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cancerous peritonitis was noted in one with MAC peritonitis
and another with M. abscessus peritonitis.
Clinical characteristics and laboratory and imaging studies
All patients in the NTM group had underlying co-morbidities,
with malignancy as the most common co-morbidity
(Table 3). In contrast, liver cirrhosis was the leading underly-
ing disease in TB peritonitis. Fever and gastrointestinal/
abdominal symptoms were the most common presentations,
which were not signiﬁcantly different between the TB and
NTM groups. Those with NTM peritonitis had lower per-
centages of lymphocytes (p 0.004) and lower albumin levels
(p 0.020) in ascites (Table 4).
Compared with patients in the ‘possible’ NTM group,
those in the ‘probable’ NTM group were more likely to have
acquired immunodeﬁciency syndrome (AIDS) (63% vs. 0%,
p <0.001), fever (25% vs. 0%, p 0.021) and a lower serum
albumin level (2.4 vs. 3.1 g/dL, p 0.030). Patients in the ‘prob-
able’ group were also more likely to receive treatment (63%
vs. 0%, p <0.001), but less likely to have malignancy (38% vs.
82%, p 0.025) (Supporting Information).
Abdominal computed tomography (CT) was performed in
31 (48%) TB and 10 (40%) NTM peritonitis patients. Of
them, 13 TB and three NTM peritonitis patients had massive
amounts of ascites. The ascites was complex and septated in
one TB patient, while two TB patients and one NTM patient
TABLE 1. Details of the eight
patients with ‘probable’ nontuber-
culous mycobacterial peritonitis
Patient no.
Ascites
Underlying
co-morbidity
Other positive
samples for
NTM
NTM comparable pathology
Culture
result
No. of
positive
cultures Specimens Findings
1 MAC 3 AIDS Blood, PE, stool Bone marrow AFB
2 MAC 3 AIDS Blood Intra-abdominal
LN
GI and AFB
3 MAC 2 AIDS, alcoholism ) Liver AFB
4 MAC 2 HCC, LC ) ) )
5 MAC 1 AIDS, alcoholism Sputum ) )
6 MAC 1 AIDS Colon tissuea ) )
7 M. chelonae 2 Breast cancer ) ) )
8 M. abscessus 1 Thyroid cancer,
DM
BAL ) )
AFB, acid-fast bacilli; AIDS, acquired immunodeﬁciency syndrome; BAL, bronchio-alveolar lavage; DM, diabetes mell-
itus; GI, granulomatous inﬂammation; HCC, hepatocellular carcinoma; LC, liver cirrhosis; LN, lymph node; MAC,
Mycobacterium avium complex; PE, pleural effusion.
aSampled by colonoscopy biopsy.
TABLE 2. Details of the 17 patients with ‘possible’ non-
tuberculous mycobacterial peritonitis
Patient no.
Ascites culture
result
Underlying
co-morbidity
1 MAC Intra-abdominal MUO
2 MAC Rectal cancer
3 MAC HCC, LC, alcoholism
4 MAC Severe CKD
5 MAC Ovarian cancer
6 MAC HCC, LC
7 MAC Ovarian cancer
8 M. fortuitum HCC, LC
19 M. fortuitum HCC, LC
10 M. chelonae LC, DM
11 M. chelonae HCC, LC
12 M. abscessus Prostate cancer
13 M. kansasii ESRD
14 M. kansasii Intra-abdominal MUO
15 Undifferentiated species Ovarian cancer
16 Undifferentiated species Gastric cancer
17 Undifferentiated species HCC
DM, diabetes mellitus; ESRD, end-stage renal disease; HCC, hepatocellular carci-
noma; LC, liver cirrhosis; MAC, Mycobacterium avium complex; MUO, malignancy
with unknown origin.
TABLE 3. Comparison of clinical characteristics of myco-
bacterial peritonitis according to causative pathogen
NTM
(n = 25)
Tuberculosis
(n = 65) p-value
Age >65 years 7 (28%) 30 (46%) 0.117
Male gender 16 (64%) 32 (49%) 0.208
Underlying co-morbiditya 25 (100%) 53 (82%) 0.021
Malignancy 17 (68%) 16 (25%) <0.001
Liver cirrhosis 7 (28%)b 31 (48%)c 0.090
Acquired immunodeﬁciency
syndrome
5 (20%) 3 (5%) 0.022
Alcoholism 3 (12%) 6 (9%) 0.695
Severe chronic kidney disease 2 (8%) 13 (20%) 0.171
Receiving peritoneal
dialysis
1 (4%) 10 (15%) 0.140
Diabetes mellitus 2 (8%) 12 (18%) 0.220
Autoimmune disease 0 4 (6%) 0.204
Initial presentation
Abdominal pain/distension 14 (56%) 25 (38%) 0.187
Gastrointestinal symptomsd 4 (16%) 7 (11%) 0.559
Fever 2 (8%) 8 (12%) 0.507
Duration of symptoms (days) 10.5 [13.2] 20.0 [32.5] 0.182
Disseminated 4 (16%) 21 (32%) 0.122
Treatment 5 (20%) 42 (65%) <0.001
Data are either no. (%) or mean [SD] unless otherwise indicated.
NTM, non-tuberculous mycobacteria.
aMultiple underlying co-morbidities were noted in 29 patients with TB peritoni-
tis (three had three co-morbidities and 26 had two) and ten patients with NTM
peritonitis (three co-morbidities in one and two in 9).
bOne had Child-Pugh class A liver cirrhosis, three class B, and three class C.
cTwo had Child-Pugh class A liver cirrhosis, 11 class B, and 18 class C.
dGastrointestinal symptoms included vomiting (n = 2), haematemesis (n = 2),
tarry stool (n = 4) and haematochezia (n = 3).
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had nodules in the omentum. One TB patient and two NTM
patients had intra-abdominal lymphadenopathy.
Seven patients with NTM peritonitis received colonos-
copy, which showed non-speciﬁc colitis in three. Of the TB
peritonitis patients, eight underwent colonoscopy and three
received endoscopic biopsy, which showed chronic colitis in
two and non-speciﬁc colitis in one.
Histopathology ﬁndings
Ten patients with TB peritonitis received peritoneal biopsy by
either laparoscopy (n = 6), laparotomy (n = 3), or image-guid-
ance (n = 1). Except for the image-guided biopsy showing
chronic inﬂammation, the others reported typical pathological
ﬁndings, including granulomatous inﬂammation in nine, acid-
fast bacilli in six, and caseous necrosis in four. Another three
TB patients received intra-abdominal biopsy (one each from
the ovary, lymph node and small intestine) and all had typical
pathological ﬁndings. One NTM patient had an intra-abdominal
lymph node biopsy, which showed granulomatous inﬂamma-
tion with acid-fast bacilli. Another NTM patient had a liver
biopsy, which revealed inﬂammation with acid-fast bacilli.
Survival analysis
Within the 6-month follow-up, 12 (48%) NTM and 21 (32%)
TB peritonitis patients died of multiple organ failure without
evidence of aetiologies or pathogens other than mycobacte-
ria. Among them, 10 (83%) NTM and 16 (76%) TB peritonitis
patients died before the results of the ascites culture became
available. In the NTM group, the 6-month mortality rate was
similar in those with malignancy (53%), AIDS (40%), liver cir-
rhosis (57%) and diabetes mellitus (50%). NTM patients with
malignancy had an insigniﬁcantly higher mortality rate than
TB patients with malignancy (9 (53%) vs. 4 (25%), p 0.101).
Similar ﬁndings were noted in patients with AIDS (2 (40%)
vs. 0, p 0.206), liver cirrhosis (4 (57%) vs. 14 (45%), p 0.566),
and DM (1 (50%) vs. 5 (42%), p 0.825).
Six-month survival was not signiﬁcantly different between
NTM and TB peritonitis (Fig. 1a) and between the ‘probable’
and the ‘possible’ NTM groups (Fig. 1b). Cox regression
analysis revealed that lack of anti-mycobacterial treatment
was the independent poor prognostic factor (Fig. 1c and
Table 5; HR, 5.83; 95% CI, 2.10–16.17).
Comparison of peritonitis from different NTM species
Patients with MAC peritonitis were younger, more likely to
have AIDS, and less likely to have cancer, diabetes mellitus
or liver cirrhosis (Table 6). The laboratory ﬁndings, 6-month
mortality rate and 6-month survival (p 0.821, log-rank test)
were not signiﬁcantly different among the three subgroups.
Discussion
Mycobacterial peritonitis has a high mortality rate and is
commonly caused by M. tuberculosis [18]. In the current
study conducted in an endemic area of TB (incidence: 62.0
persons per 100 000 populations in 2008) [21], NTM
accounted for 28% of all cases of mycobacterial peritonitis
and had a similar 6-month mortality rate as TB peritonitis.
Although analysis suggested that proper treatment could
improve survival, few NTM patients received treatment and
many died before their culture results became available.
Unfamiliarity with the clinical manifestations of NTM perito-
nitis might be a key reason for the high mortality rate. The
impact is even more serious in Taiwan because liver cirrho-
sis, an important risk factor for tuberculosis and tuberculous
peritonitis, is common due to the high prevalence of hepati-
tis B and hepatitis C virus infection [18,22,23].
Mycobacterial peritonitis, especially NTM peritonitis, is
frequently associated with underlying co-morbidities, which
compromise either local or systemic immunity with frequent
bacterial translocation [15,24,25]. Early suspicion of myco-
bacterial peritonitis is difﬁcult because of the non-speciﬁc
presentation, which is further inﬂuenced by complicated co-
morbidities. Unlike patients with TB peritonitis, those with
NTM peritonitis have relatively short disease courses (about
1 week). With low lymphocyte percentages and albumin lev-
els, their ascites can mimic spontaneous bacterial peritonitis
[26]. These ﬁndings are similar to previous observations in
patients with NTM pleurisy [27].
Few patients here received treatment for NTM peritonitis.
The low treatment rate has three possible reasons. First, ten
patients had already died before the results of the ascites
culture became available. Second, fever and other toxic signs
TABLE 4. Comparison of laboratory ﬁndings in mycobacte-
rial peritonitis according to causative pathogen
NTM
(n = 25)
Tuberculosis
(n = 65) p-value
Laboratory: Ascites
Leukocyte count (/lL) 10 008 [42 530] 1241 [1743] 0.357
Lymphocyte (%) 41 [31] 64 [29] 0.004
Neutrophil (%) 42 [36] 24 [27] 0.064
Mesothelial cells (%) 17 [21] 12 [18] 0.377
Lactate dehydrogenase (U/L) 3025 [9879] 528 [669] 0.328
Albumin (g/dL) 1.0 [0.8] 1.6 [1.0] 0.020
Glucose (mg/dL) 134 [71] 143 [92] 0.750
Laboratory: Serum
Leukocyte count (/lL) 8481 [3826] 8836 [6583] 0.815
Haemoglobin (g/dL) 10.4 [1.7] 9.9 [1.9] 0.340
Creatinine (mg/dL) 1.5 [2.5] 2.5 [2.5] 0.129
Total bilirubin (mg/dL) 4.9 [8.1] 3.8 [6.3] 0.528
Albumin (g/dL) 2.9 [0.7] 2.8 [0.7] 0.307
Data are mean [SD] unless otherwise indicated.
NTM, non-tuberculous mycobacteria.
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of infection are not common in the study patients, possibly
due to old age and the high prevalence of underlying co-
morbidity. Third, 17 (68%) of the NTM group had only one
positive ascites sample. Clinicians may consider this as labo-
ratory contamination and decide to keep observing the
patients until the diagnosis of NTM peritonitis is conﬁrmed.
Nonetheless, the clinical characteristics and outcomes are
similar in the ‘probable’ and the ‘possible’ NTM groups. In
addition, because prognosis is poor if left untreated, invasive
diagnostic procedures, along with histopathological examina-
tions and bacteriological studies, may be justiﬁed, especially if
the bleeding tendency can, at least partially, be corrected
[16,18,27].
FIG. 1. Survival curves of patients with mycobacterial peritonitis
were plotted using the Kaplan–Meier method and compared using
the log-rank test according to (a) causative pathogen (non-tubercu-
lous mycobacterial (NTM) or Mycobacterium tuberculosis), (b) ‘proba-
ble’ or ‘possible’ NTM group, and (c) treatment status. Black dots
represent patients still alive at the end of the study.
TABLE 5. Factors possibly associated with 6-month survival
Characteristics
p-value
Univariate Multivariate
Age: ‡65 vs. <65 years 0.842
Sex: male vs. female 0.834
Malignancy: presence vs. absence 0.652
AIDS: presence vs. absence 0.470
DM: presence vs. absence 0.713
Liver cirrhosis: presence vs. absence 0.018 0.401
Severe CKD: presence vs. absence 0.319
Serum albumin level: <3.5 vs. ‡3.5 g/dL 0.248
Serum total bilirubin: >1.5 vs. £1.5 mg/dL <0.001 0.228
Ascites leukocyte count: £500 vs. >500/lL <0.001 0.088
Ascites lymphocyte ratio: >50 vs. £50% 0.062
Ascites LDH: >460 vs. £460 IU/L 0.145
Ascites albumin level: £1.3 vs. >1.3 g/dL 0.001 0.081
Presentation to diagnosis: >6 vs. £6 weeks 0.047 0.073
Biopsya: yes vs. no 0.209
Causing pathogens: NTM vs. M. tuberculosis 0.237
Anti-mycobacterial treatment: no vs. yes <0.001 0.001b
AIDS, acquired immunodeﬁciency syndrome; CKD, chronic kidney disease; DM,
diabetes mellitus; LDH, lactate dehydrogenase; NTM, non-tuberculous mycobac-
teria.
aIncluding the peritoneum or intra-abdominal organ.
bHR, 5.83; 95% CI, 2.10–16.17.
TABLE 6. Comparison of clinical characteristics in patients
with peritonitis due to different non-tuberculous mycobac-
teria
MAC
(n = 13)
RGMa
(n = 7)
Other speciesb
(n = 5) p-value
Age >65 years 1 (8%) 3 (43%) 3 (60%) 0.060
Male gender 8 (62%) 4 (57%) 4 (80%) 0.520
Underlying co-morbidity 13 (100%) 7 (100%) 5 (100%) 0.149
Malignancy 7 (54%) 6 (86%) 4 (80%) 0.001
Liver cirrhosis 3 (23%) 4 (57%) 0 0.071
Diabetes mellitus 0 0 2 (40%) 0.013
Alcoholism 3 (23%) 0 0 0.207
Acquired immunodeﬁciency
syndrome
5 (38%) 0 0 0.001
Severe chronic kidney disease 1 (8%) 0 1 (20%) 0.438
Disseminated 3 (23%) 1 (14%) 0 0.339
Treatment 5 (38%) 0 0 <0.001
Six-month mortality 7 (54%) 3 (43%) 2 (40%) 0.508
Data are no. (%) unless otherwise indicated.
MAC, Mycobacterium avium complex; RGM, rapidly growing mycobacteria.
aIncluded three patients infected by M. chelonae, two by M. abscessus, and two
by M. fortuitum.
bOther species included Mycobacterium kansasii in two patients and undifferenti-
ated species in three.
250 Clinical Microbiology and Infection, Volume 18 Number 3, March 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 246–252
Mycobacterium avium complex remains the most common
pathogen in NTM peritonitis, pulmonary NTM infection
(43%) and extra-pulmonary NTM infection in Taiwan [27–
29]. Because MAC is a well-documented pathogen of
opportunistic infection in AIDS patients, those with MAC
peritonitis receive treatment more frequently than those
with other NTM species. However, the 6-month mortality
rate and survival are similar in MAC and in other NTM
peritonitis. This ﬁnding has two possible explanations. First,
none of the patients with peritonitis due to other NTM
had HIV infection. Second, infections caused by NTM spe-
cies other than MAC might have a less virulent course
[15]. These ﬁndings further emphasize the importance of
maintaining a high index of suspicion of mycobacterial peri-
tonitis and prompt treatment for compromised hosts in
endemic areas.
This study has several limitations. First, and most impor-
tant, the diagnostic procedures and treatment protocols are
not standardized in the retrospective study. The incidence
of mycobacterial peritonitis is very likely underestimated.
The values of the ascites adenosine deaminase, nucleic acid
ampliﬁcation test and interferon-gamma release assay for
the early diagnosis of mycobacterial peritonitis are not eval-
uated. Second, the possibility of co-bacterial infection may
be also underestimated because the yield rate of ascites
culture for bacteria is only 40–50% [30]. Third, because the
study was conducted in a medical centre and many patients
with severe underlying co-morbidities were included, the
mortality rate may have been overestimated. However, this
should not be a serious bias because only compromised
hosts acquire mycobacterial peritonitis, especially due to
NTM. Finally, the small number of patients limits the statis-
tical power of inter-group comparisons. More studies are
warranted to further explore differences among disease
subgroups.
Conclusions
In Taiwan, an endemic area for TB, NTM accounted for 28%
of all mycobacterial peritonitis cases and has worse survival
if left untreated. MAC is the most common NTM species.
Unlike those of TB peritonitis, the clinical manifestations of
NTM peritonitis mimic spontaneous bacterial peritonitis,
with a short disease course (1–2 weeks) and relatively low
lymphocyte percentage in ascites. Thus, NTM peritonitis
should be kept in mind when evaluating peritonitis with no
other identiﬁed microorganism except NTM and when the
clinical infection does not improve under broad-spectrum
empirical antibiotic treatment.
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